(Q58149661)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476786%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

editorial

0 references

title

Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476786%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

0 references

non-alcoholic fatty liver

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476786%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Konstantinos Tziomalos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476786%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Asterios Karagiannis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476786%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Georgios N Daskalopoulos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476786%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Dimitri P Mikhailidis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476786%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

English

0 references

publication date

1 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476786%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476786%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476786%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476786%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

167-171

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476786%20AND%20SRC:MED&resulttype=core&format=json

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Non-alcoholic fatty liver disease: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Do we need to consider inflammatory markers when we treat atherosclerotic disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Non-alcoholic fatty liver disease and increased risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Targeting vascular risk in patients with metabolic syndrome but without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Therapeutic association of atorvastatin and insulin in cardiac ischemia: study in a model of type 2 diabetes with hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Effects of 1-O-hexyl-2,3,5-trimethylhydroquinone on carbon tetrachloride-induced hepatic cirrhosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Lipid-lowering agents and new onset diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Current best treatment for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Advancing therapy for hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Statins and renal function in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.561363

10.3109/07853890.2011.561363

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476786%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference